Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Innovus Solarex Biotech Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, Benjamin P Blumel. The prosecution is centralized within 1 distinct art unit. Benjamin P Blumel is the busiest examiner, managing 1 busiest examiner pending action. This 1 action represents the total pending office actions for the company.
For the practitioner, the prosecution strategy in the Biotechnology & Pharmaceuticals area is currently limited to this 1 distinct examiner, making their specific examination style the most significant factor in the case's progress. The presence of 1 distinct art unit indicates that the technical subject matter is being reviewed by a single administrative group. Benjamin P Blumel is the only official handling the 1 pending office action, so the legal team can dedicate all resources to addressing his specific concerns. This 1 busiest examiner pending action is the only active matter, which allows for a highly focused response. Practitioners should prepare for a direct negotiation with the 1 distinct examiner to move the Biotechnology & Pharmaceuticals application toward allowance. The success of the current filing depends on a single relationship with the assigned official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18884570 | NANOBODY CLASSICAL SWINE FEVER VIRUS (CSFV)-E0-Nb1 AGAINST CSFV E0 PROTEIN, GENE ENCODING THE SAME AND USE THEREOF | BLUMEL, BENJAMIN P | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18884570 | NANOBODY CLASSICAL SWINE FEVER VIRUS (CSFV)-E0-Nb1 AGAINST CSFV E0 PROTEIN, GENE ENCODING THE SAME AND USE THEREOF | BLUMEL, BENJAMIN P | 1671 | §112 | Non-Final OA | — | Pending | Sep 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInnovus Solarex Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Benjamin P Blumel has the most, with 1 of Innovus Solarex Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
